Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elitecon International  Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Elitecon International  Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Elitecon International clocked Q1 FY26 standalone revenue of ₹199.23 crores vs ₹49.56 crores. 
• On the profit front, Elitecon International earned a standalone PAT of ₹20.41 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹4.54 crore. 
• Standalone PAT rose for the first quarter of FY26, was 349.99% YoY, and revenue rose 301.98% YoY. 

Elitecon International  Share Price Performance

On the opening bell of 13th August 2025, the shares of Elitecon International opened at ₹300.50 per share. However, the initial gains are sustained as of now, and Elitecon International shares are trading at ₹301.50 per share, higher than their opening price. 

Considering the long-term performance, Elitecon International shares have yielded close to 27,218.18% returns in the past 1 year, and 5-year returns stand at 22,325.37%. Over the maximum timeframe, the Elitecon International share provided 22,325.37% returns to investors. However, one must ignore the risk of volatility in the stock market and invest in Elitecon International shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Finolex Cables Q1 Results FY26: Q1 PAT Falls 33.33% to ₹162.62 Crore; Revenue Up 13.41% YoY

Abbott India Q1 Results FY26: Q1 PAT Rises 11.54% to ₹365.86 Crore; Revenue Up 11.60% YoY

Jyothy Labs Q1 Results FY26: Q1 PAT Falls 4.95% to ₹96.73 Crore; Revenue Up 1.35% YoY

Zydus Lifesciences Q1 Results FY26: Q1 PAT Rises 3.30% to ₹1,466.80 Crore; Revenue Up 5.90% YoY

Bombay Burmah Trading Q1 Results FY26: Q1 PAT Soars 8.28% to ₹240.70 Crore; Revenue Up 8.73% YoY

Alkem Laboratories Q1 Results FY26: Q1 PAT Rises 21.85% to ₹664.26 Crore; Revenue Up 11.19% YoY

Natco Pharma Q1 Results FY26: Q1 PAT Falls 28.09% to ₹480.70 Crore; Revenue Down 2.47% YoY

Hindalco Q1 Results FY26: Q1 PAT Rises 30.00% to ₹4,004.00 Crore; Revenue Up 13.00% YoY